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Abstract
Introduction—Mice with a complete absence of tissue factor (TF) die during embryonic 
development whereas mice with low levels of TF (Low-TF mice) survive to adulthood. Low-TF 
mice exhibit spontaneous hemorrhage in various organs, including the lung. In contrast, mice can 
survive without protease-activated receptor (PAR)-4, which is the major thrombin receptor on 
mouse platelets. We determined the effect of combining a deficiency PAR-4 (primary hemostasis) 
with a deficiency in TF (secondary hemostasis) on embryonic development and survival of adult 
mice.
Materials and Methods—Low-TF mice (mTF−/−, hTF+/+) were crossed with PAR-4−/− mice to 
generate heterozygous mice (mTF+/−, hTF+/−, PAR-4+/−). These mice were intercrossed to 
generate Low-TF mice lacking PAR-4. Mice surviving to wean were genotyped and survival was 
monitored for 6 months.
Results—We observed the expected number of Low-TF,PAR-4−/− mice at wean indicating 
survival in utero and after birth. However, an absence of PAR-4 was associated with premature 
death of all Low-TF,PAR-4−/− mice in the 6 month observational period. This compares with 40% 
death of the Low-TF,PAR-4+/+ mice (p=0.003). Low-TF,PAR-4+/− mice had an intermediate 
phenotype with 55% of the mice dying within 6 months. The primary cause of mortality of Low-
TF,PAR-4−/− mice was pulmonary hemorrhage.
Conclusions—Low-TF,PAR-4−/− mice survive into adulthood, but combining a deficiency of 
primary hemostasis (PAR-4 deficiency) with secondary hemostasis (low levels of TF) leads to 
premature death primarily due to pulmonary hemorrhage.
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INTRODUCTION
Tissue factor (TF) is the major physiological activator of coagulation. After vessel injury, 
thrombin generated by the coagulation cascade cleaves fibrinogen to fibrin that stabilizes the 
platelet clot. Previous studies have shown that embryos with a complete deficiency of TF die 
at embryonic day ~E9.5 due to a defect in yolk sac vascular development1–3. Similarly, a 
complete absence of other components of the clotting cascade, namely FVII, FV, FX, and 
prothrombin, leads to death due to either mid-gestational yolk sac vascular defects in 
embryos or hemorrhage in neonates after birth4–8. A deficiency of fibrinogen is not 
associated with any mid-gestational death, although there is a variable degree of death (10–
50%) due to abdominal bleeds after birth depending on genetic background9,10.
In mice, thrombin also activates platelets via protease-activated receptor (PAR)-411. PAR-4 
deficient mice survive to adulthood but have increased bleeding after tail transection11. 
However, a combined deficiency of both fibrinogen and PAR-4 results in fatal neonatal 
bleeding similar to the absence of prothrombin12. Similar results were observed when a 
deficiency of fibrinogen was combined with thrombocytopenia caused by an absence of the 
transcription factor NF-E213. These results indicate that thrombin has two major functions: 
cleavage of fibrinogen to fibrin and activation of platelets12–14.
Various mice have been generated with reduced levels of procoagulant proteins. For 
instance, Low-TF mice express low levels (~1% of wild-type levels) of human TF from a 
minigene on a mouse TF null background15. The majority of Low-TF mice (~80%) survive 
to wean but exhibit spontaneous bleeding in the lung, heart, testis and brain later in life, and 
also have hemostatic defects in the placenta and uterus15–19. Mice have been generated with 
5–10% of wild-type prothrombin and live to adulthood without excess bleeding except after 
tail transection or in traumatic situations, such as fighting20. A transgene expressing FV 
from an albumin promoter at less than 0.1% of wild-type FV activity was able to support the 
survival of adult mice but was unable to rescue FV null embryos21. In addition to the 
generation of mice with defects in hemostasis, other mice have been generated that are 
prothrombotic, such as mice lacking the anticoagulant tissue factor pathway inhibitor 
(TFPI), as well as mice with mutations in FV (FV Leiden) and thrombomodulin 
(TMpro)22–24.
Mice with pro-hemorrhagic or pro-coagulant phenotypes have been intercrossed to either 
rebalance thrombin generation or exacerbate a mild phenotype8,25. For example, combining 
FV Leiden mice with TFPI+/− mice is lethal26. A deficiency of TFPI leads to intrauterine 
death due to a consumptive coagulopathy22; however, the embryonic lethality of TFPI 
deficient mice can be rescued by reducing levels of TF using Low-TF mice27. The chronic 
lung bleeding and fatal pulmonary hemorrhages that are observed in adult Low-TF mice 
were also markedly reduced when TFPI was absent. Similarly, other mutations that lead to 
intrauterine death, such as endothelial cell protein C receptor, thrombomodulin, and 
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antithrombin deficiency can be rebalanced by decreasing levels of TF28,29. Recently, it was 
shown that a deficiency in PAR-4 rescued ~40% of TFPI null embryos30. These mice lived 
to adulthood but were more prothrombotic with fibrin deposition in the liver and higher 
susceptibility to TF-induced pulmonary embolism.
In this study we analyzed the effect of combining a defect in primary hemostasis (PAR-4 
deficiency) with a defect in secondary hemostasis (low levels of TF) on development during 
embryogenesis and survival in adulthood.
MATERIAL AND METHODS
Mice
All studies were performed in accordance with the guidelines of the animal care and use 
committees of UNC-Chapel Hill and comply with National Institutes of Health guidelines. 
Low-TF mice (mTF−/−,hTF+/+) were generated as previously described 15 and were 
backcrossed 6 generation to a C57BL/6J genetic background. We observed ~80% of the 
expected number of Low-TF mice at wean on this genetic background27. Genotyping for the 
wild-type mTF allele and the hTF transgene was performed by polymerase chain reaction 
(PCR) as described previously15. The mutant TF allele was identified using a primer in the 
promoter (mTF-1097) and a primer in PGK-NEO. We use the notation +/− to describe the 
status of the mTF alleles in Low-TF mice. All Low-TF mice have at least one copy of the 
hTF transgene. PAR4−/− breeding pairs on a C57BL/6J background were a gift from Dr. 
Shaun Coughlin, University of California, San Francisco11. Low-TF mice (mTF+/−,hTF+/+) 
mice were crossed with PAR4+/− mice and mice with the genotype mTF+/−,hTF+/−,PAR-4+/− 
were intercrossed.
Postmortem analysis of mice
All dead mice that were not decomposed were analyzed for bleeding. Fatal bleeding was 
mostly observed in the lungs or brain. Lungs were fixed and sectioned for histological 
analysis.
Data Analysis
Statistical analysis of the distribution of genotypes was analyzed by Chi-square test 
assuming the null hypothesis. Log-rank analysis was used to determine statistical 
significance of the survival of the different mice. Differences were determined to be 
statistically significant at a P value of <0.05.
RESULTS
Generation of Low-TF,PAR-4−/− mice
Previously, we have observed ~80% survival of Low-TF mice at wean on this C57BL/6J 
genetic background (backcrossed 7 generations)27. We examined the frequency of Low-
TF,PAR-4−/− mice in two different breeding strategies. First, we intercrossed 
mTF+/−,hTF+/−,PAR-4+/− mice. We generated 69 mice and found that at wean the number of 
Low-TF,PAR-4−/− mice did not differ significantly from the expected number (p = 0.90) 
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(Table 1). As expected from our earlier study27, all three Low-TF groups had slightly lower 
numbers than expected due to ~20% embryonic lethality. In a second breeding we crossed 
mTF−/−,hTF+/−, PAR-4+/− mice with mTF+/−,hTF+/−,PAR-4+/− mice. We generated 39 mice 
in this breeding. As expected from the first breeding, the number of Low-TF,PAR-4−/− mice 
observed at wean did not differ from the expected number (p=0.62) (Table 1). These results 
indicate that an absence of PAR-4 does not affect the survival of Low-TF mice during 
embryonic development and early adulthood.
Survival of Low-TF mice with different levels of PAR-4
In a previous study27 we observed a relatively high rate of mortality of Low-TF mice on the 
same C57BL/6J background as used in this study (backcrossed 7 generations) within 6 
months. We monitored mice surviving to wean over a 6-month period to determine if 
reducing levels of PAR-4 affect the survival of Low-TF mice. We used 
mTF+/+,hTF+/−,PAR-4−/− mice as controls because these mice exhibit normal survival11. We 
observed that 100% of the Low-TF,PAR-4−/− mice died during the observation period of 6 
months (Figure 1). The median survival time of these mice was 83 days. In contrast, only 
40% of the Low-TF,PAR-4+/+ mice died during the observational period (p=0.003), and 
these mice had a median survival time of >180 days. Low-TF−/−,PAR-4+/− mice had an 
intermediate phenotype with 55% of the mice dying within 6 months and a median survival 
time of 145 days. All experimental groups had a significantly reduced survival compared to 
control PAR-4 deficient mice owing to the hemostatic defect caused by Low-TF. These 
results indicate that PAR-4 is required to maintain hemostasis in Low-TF mice.
Pulmonary hemorrhage is increased in mice with low levels of tissue factor and PAR-4 
deficiency
In a previous study using Low-TF mice on the same C57BL/6J background we observed a 
high rate of death due to pulmonary hemorrhage within a 6 month period27. In the current 
study we two Low-TF,PAR-4+/+ mice died of pulmonary hemorrhage and one died of an 
intracranial hemorrhage (Table 2). All Low-TF, PAR-4−/− mice that were analyzed (n=8) 
died of pulmonary hemorrhage (Table 2) (Figure 2). Similarly, the majority of Low-
TF,PAR-1+/− mice that were analyzed (n=14) died from pulmonary hemorrhage (Table 2). 
Two testicular bleeds (1 Low-TF,PAR-4−/−, 1 Low-TF,PAR-4+/−) and one gastrointestinal 
hemorrhage (Low-TF,PAR-4+/−) were observed in mice that had died from pulmonary 
hemorrhage. These results indicate that combining defects in primary and secondary 
hemostasis leads to fatal pulmonary hemorrhage in mice.
DISCUSSION
Our results show that a deficiency of PAR-4 does not affect the survival of Low-TF mice 
during embryonic development or early adulthood. Previous studies showed that combining 
fibrinogen deficiency with either a PAR-4 deficiency or thrombocytopenia led to death of all 
mice shortly after birth12,13. The key difference of our study is that due to low levels of TF 
small amounts of thrombin are still present, which we propose prevents embryonic lethality 
and developmental defects seen in other studies.
Bode and Mackman Page 4
Thromb Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Our results demonstrate that PAR-4 deficiency led to a dose-dependent increase in mortality 
when combined with low levels of TF. While only 40% of the Low-TF mice with wild-type 
PAR-4 died during the 6-month observation, all of the Low-TF mice with PAR-4 deficiency 
died. No mice died during the first one and a half months. This observation may be 
explained by accumulation of small bleeds that have not reached a critical threshold this 
early in life to cause death. The cause of death was mainly pulmonary hemorrhage. This 
result indicates that in the setting of reduced coagulation with minimal TF the activation of 
PAR-4 is important for hemostasis, particularly in the lung. Our results suggest that other 
primary activators of platelets, such as collagen, do not substitute for the lack of activation 
by thrombin through PAR-4.
Although an absence of PAR-4 on platelets is the most likely explanation for our 
observations, it is possible that PAR-4 on other cell types may also contribute to maintain 
hemostasis. Recently, we examined the importance of platelets in maintaining hemostasis in 
Low-TF mice31. We found that Low-TF mice treated with clopidogrel showed significantly 
more bleeding due to instability of the hemostatic plug compared to wild-type controls that 
were treated with clopidogrel31.
Compared to mice expressing low levels of prothrombin that survived to adulthood without 
major spontaneous bleeds, the phenotype of Low-TF,PAR-4−/− mice studied here is more 
severe due to both a lower level of thrombin activity and an absence of thrombin activation 
of platelets (Figure 3). Low prothrombin mice have 5–10% of wild-type thrombin levels and 
are therefore able to activate platelets through PAR-4 in the event of a bleed20. This is not 
possible in the Low-TF,PAR4−/− mice studied here due to a lack of PAR-4.
The coagulation system is regulated in a tissue-specific manner32. Thrombomodulin, for 
example, is an important anticoagulant in the lung, and heart, but not in the liver32. The 
fibrinolytic pathway is important in all three organs, while none of these mechanisms are 
essential in the brain32. A possible explanation for the high rate of pulmonary hemorrhage in 
the current study may be vessel damage induced by continuous mechanical stress in 
conjunction with a limited capacity to contain bleeds into the empty spaces of the alveoli 
once the hemostatic barrier is compromised. Mechanical stress is also experienced by the 
heart, which leads to small bleeds into the myocardium that eventually cause cardiac fibrosis 
in Low-TF mice16. Indeed, Low-TF,PAR-4−/− mice exhibited similar bleeds (data not 
shown). However, bleeds in the myocardium are likely to be contained by the tight 
organization of the cardiac myocytes. Intracranial hemorrhages were observed in only two 
mice. A previous study examined the effect of genetically eliminating prothrombin in adult 
mice and found that these mice died within 7 days of either cardiac or intracranial 
hemorrhage but did not show any signs of pulmonary hemorrhage33. This discrepancy may 
be because high levels of TF are expressed in the heart and brain to provide additional 
hemostatic protection34 whereas the current study uses mice with low levels of TF.
In summary, our results indicate that combining genetic defects in primary and secondary 
hemostasis results in fatal hemorrhage in adult mice. Interestingly, both antiplatelet and 
anticoagulant drugs are used in some patients, such as those with both cardiovascular disease 
and atrial fibrillation. In the ATLAS ACS-TIMI 51 trial addition of the FXa inhibitor 
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rivaroxaban to antiplatelet drugs led to a dose-dependent increase in major bleeding but not 
fatal bleeding35. Our study suggests that combing antiplatelet and anticoagulant drugs may 
increase susceptibility to pulmonary hemorrhage. Understanding organ-specific hemostasis 
may allow us to predict or prevent bleeding events in patients taking multiple anti-
thrombotic drugs.
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Highlights
• Mice with a deficiency of TF and PAR-4 survive to wean
• Combining low levels of TF with a deficiency of PAR-4 leads to 
premature death
• The primary cause of death of Low-TF,PAR-4−/− mice is pulmonary 
hemorrhage
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Figure 1. Survival of Low-TF mice with different levels of PAR-4
The survival of all experimental groups is significantly reduced compared to the control 
group (TF+/+,PAR-4+/+; n=7). Low-TF,PAR-4−/− (n=10) show significantly lower survival 
compared to Low-TF,PAR-4+/+ (n=10) and Low-TF,PAR-4+/− (n=30) mice (** p<0.01). 
mTF: mouse tissue factor. hTF+ indicates that at least one allele of human TF is present 
(hTF+/− or hTF+/+).
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Figure 2. Lung and brain bleeds in Low-TF mice lacking PAR-4
Gross pictures of lungs and brains and histology pictures of the lungs of control mice (A–C), 
Low-TF,PAR-4−/− mice (D–E), and a Low-TF,PAR-4+/− mouse (F).
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Figure 3. Summary of the effect of decreasing levels of tissue factor, prothrombin or PAR-4 in 
mice
Genetic defects in tissue factor (TF), prothrombin(PT) and/or PAR-4 are shown with the 
effect on fibrin formation and platelet activation (Plt act.).
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Table 2
Cause of death. Cause of death during the 6-month observation period was analyzed by necropsy. hTF+ 
indicates that at least one allele of human TF is present (hTF+/− or hTF+/+).
mTF−/−, hTF+, PAR-4−/− mTF−/−, hTF+, PAR-4+/− mTF−/−, hTF+, PAR-4+/+ mTF+/+, hTF+, PAR-4−/−
pulmonary hemorrhage
intracranial hemorrhage
not analyzed
8 13 2 0
0 1 1 0
2 5 0 0
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